Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IVIG vs plasma exchange: which works best for myasthenic crisis?

NCT ID NCT07532707

Disease control Sponsor: Damascus University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments—intravenous immunoglobulin (IVIG) and plasma exchange (PLEX)—for people experiencing a myasthenic crisis, a severe episode of muscle weakness in myasthenia gravis. Fifty adults were treated with either IVIG or PLEX, and their improvement was measured after 14 days. The goal is to see which treatment is more effective and identify common triggers for these crises.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intravenous Immunoglobulin (IVIG) and Plasma Exchange (PLEX)
What this could lead to
If this study shows one treatment works better, it could help doctors choose the best option for managing severe myasthenic crises.
What could go wrong
This is a small, single-center study with only 50 participants, so results may not apply broadly. It compares two existing treatments, not a new breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Sep 2022

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed Diagnosis: Patients with newly diagnosed or previously confirmed Myasthenia Gravis (MG) based on clinical evaluation and confirmed by electromyography (EMG). * Severity: Patients presenting with myasthenic crisis or severe exacerbation. * Age: 18 years and older. * Treatment Necessity: Patients requiring rapid immunomodulating therapy (either IVIG or PLEX). * Informed Consent: Participants or their legal guardians must be able and willing to provide written informed consent. Exclusion Criteria: * Medical Contraindications: Severe renal failure (contraindication for IVIG) or hemodynamic instability (contraindication for PLEX). * Alternative Conditions: Presence of other neuromuscular disorders or congenital myasthenia. * Pregnancy: Pregnant or breastfeeding women. * Consent: Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myasthenia gravis (MG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myasthenia gravis (MG) Myasthenic crisis

Contacts and locations

Locations

  • Damascus University

    Damascus, Syria

More trials for these conditions

Other studies related to the condition(s) this trial covers.